Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

October 6, 2017: By Jon Swedien
SMILE laser vision correction procedure

SMILE laser vision correction procedure

Carl Zeiss Meditec announced Sept. 28 that doctors performing laser vision correction surgery using the company’s small-incision lenticule extraction (SMILE) technology have now surpassed 1 million procedures worldwide.

SMILE is being performed regularly by more than 1,300 surgeons in over 65 countries, Zeiss said.

A flapless procedure, SMILE requires only one laser to perform the treatment. During SMILE, doctors correct patients’ refractive errors using the VisuMax femtosecond laser. With the laser, surgeons create a thin disc-shaped lenticule within the cornea, which is then removed through a small incision on the surface of the cornea, also created by the laser, thereby achieving the desired vision correction.

Because the procedure requires only a small incision, it leaves the outer corneal layer largely intact, thus potentially contributing to the cornea’s stability (both biomechanical and refractive) after surgery and to fast visual recovery, Zeiss said.

The company is based in Jena, Germany.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022